Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Current Assets (2024 - 2025)

Historic Current Assets for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to $124.1 million.

  • Xilio Therapeutics' Current Assets rose 9600.53% to $124.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.1 million, marking a year-over-year increase of 9600.53%. This contributed to the annual value of $60.2 million for FY2024, which is N/A changed from last year.
  • Xilio Therapeutics' Current Assets amounted to $124.1 million in Q3 2025, which was up 9600.53% from $123.7 million recorded in Q2 2025.
  • Over the past 5 years, Xilio Therapeutics' Current Assets peaked at $124.1 million during Q3 2025, and registered a low of $60.2 million during Q4 2024.